Omada Health (NASDAQ:OMDA) CFO Sells $26,262.96 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CFO Steven Cook sold 1,884 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $13.94, for a total transaction of $26,262.96. Following the sale, the chief financial officer directly owned 200,512 shares in the company, valued at approximately $2,795,137.28. This represents a 0.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Omada Health Trading Down 1.3%

OMDA opened at $13.93 on Friday. The firm has a market capitalization of $820.83 million and a PE ratio of -81.94. The firm has a 50 day moving average of $13.76 and a two-hundred day moving average of $18.20. Omada Health, Inc. has a 12-month low of $10.28 and a 12-month high of $28.40.

Omada Health (NASDAQ:OMDA) last issued its quarterly earnings data on Thursday, March 5th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.12. The firm had revenue of $75.85 million for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Cigna Investments Inc. New bought a new position in shares of Omada Health during the third quarter valued at approximately $76,161,000. Fortress Investment Group LLC bought a new position in shares of Omada Health during the 2nd quarter valued at $2,878,000. BIT Capital GmbH acquired a new position in shares of Omada Health during the 3rd quarter valued at about $13,639,000. Bellevue Group AG acquired a new stake in Omada Health in the 2nd quarter worth approximately $4,575,000. Finally, Federated Hermes Inc. bought a new stake in Omada Health during the second quarter worth approximately $9,150,000.

Analyst Ratings Changes

OMDA has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Omada Health in a report on Thursday, January 22nd. Wall Street Zen raised shares of Omada Health from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. Canaccord Genuity Group dropped their target price on shares of Omada Health from $28.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Morgan Stanley reduced their target price on shares of Omada Health from $32.00 to $30.00 and set an “overweight” rating for the company in a report on Friday, March 6th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $26.00 price objective on shares of Omada Health in a research report on Friday, January 16th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Omada Health has a consensus rating of “Moderate Buy” and a consensus target price of $23.60.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.